CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance

Prostate

Volumn 74, Issue 6, 2014, Pages 602-617

  Ni, Jie ^a,b   Cozzi, Paul J ^a,b   Hao, Jing L ^a,b   Beretov, Julia ^a,b   Chang, Lei ^a,b   Duan, Wei ^c   Shigdar, Sarah ^c   Delprado, Warick J ^d   Graham, Peter H ^a,b   Bucci, Joseph ^a,b   Kearsley, John H ^a,b   Li, Yong ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d Douglass Hanly Moir Pathology   (Australia)

Author keywords

CD44 variant 6; chemoresistance; PI3K Akt mTOR pathway; prostate cancer; radioresistance; Wnt pathway

Indexed keywords

BETA CATENIN; CD44V6 ANTIGEN; HYALURONIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MATRIGEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTIEN WNT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CHEMORADIOTHERAPY; COLONY FORMATION; CONFOCAL MICROSCOPE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

CD44 VARIANT 6; CHEMORESISTANCE; PI3K/AKT/MTOR PATHWAY; PROSTATE CANCER; RADIORESISTANCE; WNT PATHWAY;

ANTIGENS, CD44; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LYMPHATIC METASTASIS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84897020336     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22775     Document Type: Article

References (66)

1. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF,. New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol 2011; 60 (2): 279-290.
2. Thoms J, Goda JS, Zlotta AR, Fleshner NE, van der Kwast TH, Supiot S, Warde P, Bristow RG,. Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol 2011; 8 (2): 107-113.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26 (2): 242-245.
5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators T,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
6. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D, Group EGTC,. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20 (7): 1264-1269.
7. Nagano O, Okazaki S, Saya H,. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013; 32 (44): 5191-5198.
8. Naor D, Sionov RV, Ish-Shalom D,. CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319.
9. Hao JL, Ni J, Graham P, Cozzi P, Bucci J, Kearsley J, Li Y,. The CD44 isoforms in prostate cancer metastasis and progression. World J Cancer Res 2013; 1 (1): 3-14.
10. Khan SA, Cook AC, Kappil M, Gunthert U, Chambers AF, Tuck AB, Denhardt DT,. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005; 22 (8): 663-673.
11. Akisik E, Bavbek S, Dalay N,. CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res 2002; 8 (1): 36-40.
12. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY,. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007; 67 (5): 2089-2097.
13. Mulder JW, Wielenga VJ, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST, Offerhaus GJ,. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 1995; 36 (1): 76-80.
14. Christofori G,. Changing neighbours, changing behaviour: Cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003; 22 (10): 2318-2323.
15. Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, Kanai Y, Kakizoe T,. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998; 89 (10): 1033-1040.
16. Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ, Pals ST,. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344 (8935): 1470-1472.
17. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M,. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998; 186 (2): 157-164.
18. Ayhan A, Tok EC, Bildirici I, Ayhan A,. Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecol Oncol 2001; 80 (3): 355-358.
19. Chen H, Hao J, Wang L, Li Y,. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 2009; 101 (3): 432-440.
20. Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kearsley JH, Li Y,. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS ONE 2011; 6 (9): e24405.
21. Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado WJ, Russell PJ, Li Y,. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 2010; 103 (7): 1008-1018.
22. Xiao W, Graham PH, Power CA, Hao J, Kearsley JH, Li Y,. CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin Exp Metastasis 2012; 29 (1): 1-9.
23. Wang L, Chen H, Liu F, Madigan MC, Power CA, Hao J, Patterson KI, Pourgholami MH, O'Brien PM, Perkins AC, Li Y,. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 2011; 300 (2): 122-133.
24. Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y,. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS ONE 2012; 7 (8): e40716.
25. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, Li Y,. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22 (7): 565-573.
26. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB,. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63 (18): 5821-5828.
27. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ,. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate 1998; 34 (3): 162-168.
28. Gao AC, Lou W, Dong JT, Isaacs JT,. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57 (5): 846-849.
29. Noordzij MA, van Steenbrugge GJ, Verkaik NS, Schroder FH, van der Kwast TH,. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997; 3 (5): 805-815.
30. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma VM,. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 2001; 39 (2): 138-144.
31. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB,. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 2004; 112 (1): 121-129.
32. Takahashi S, Kimoto N, Orita S, Cui L, Sakakibara M, Shirai T,. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett 1998; 129 (1): 97-102.
33. Liotta LA, Delisi C, Saidel G, Kleinerman J,. Micrometastases formation: A probabilistic model. Cancer Lett 1977; 3 (3-4): 203-208.
34. Ween MP, Oehler MK, Ricciardelli C,. Role of Versican, Hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011; 12 (2): 1009-1029.
35. Yu Q, Stamenkovic I,. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13 (1): 35-48.
36. Sethi S, Macoska J, Chen W, Sarkar FH,. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010; 3 (1): 90-99.
37. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H,. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012; 72 (7): 1878-1889.
38. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119 (6): 1420-1428.
39. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C,. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121 (3): 1064-1074.
40. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM,. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67 (3): 1030-1037.
41. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100 (7): 3983-3988.
42. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, Ailles LE,. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: Correlation with tumor aggressiveness. Head Neck 2012; 34 (1): 42-49.
43. Yang YM, Chang JW,. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008; 26 (7): 725-733.
44. Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M, Sleeman J,. CD44 expression and regulation during mammary gland development and function. J Cell Sci 2000; 113 (Pt 14): 2619-2630.
45. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I,. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011; 6 (9): e24217.
46. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E,. Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011; 17 (10): 1225-1227.
47. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP,. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008; 105 (36): 13427-13432.
48. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG,. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65 (13): 5506-5511.
49. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP,. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68 (11): 4311-4320.
50. Shi X, Gipp J, Bushman W,. Anchorage-independent culture maintains prostate stem cells. Dev Biol 2007; 312 (1): 396-406.
51. Martin GS,. Cell signaling and cancer. Cancer Cell 2003; 4 (3): 167-174.
52. Bitting RL, Armstrong AJ,. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20 (3): R83-R99.
53. Zhan JF, Wu LP, Chen LH, Yuan YW, Xie GZ, Sun AM, Liu Y, Chen ZX,. Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation. Cell Oncol (Dordr) 2011; 34 (5): 451-456.
54. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M,. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30 (2): 193-204.
55. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L,. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 2011; 18 (18): 2715-2726.
56. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA,. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009; 106 (1): 268-273.
57. Lim M, Chuong CM, Roy-Burman P,. PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm Cancer 2011; 2 (5): 298-309.
58. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H,. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004; 58 (3): 259-268.
59. Dihlmann S, von Knebel Doeberitz M,. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113 (4): 515-524.
60. Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, Sahai R, Geller DA, Hussain SP,. Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 2006; 66 (14): 7024-7031.
61. Sell S,. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51 (1): 1-28.
62. Yuan D, Liu L, Gu D,. Transcriptional regulation of livin by beta-catenin/TCF signaling in human lung cancer cell lines. Mol Cell Biochem 2007; 306 (1-2): 171-178.
63. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S, Zoller M,. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177 (2): 443-455.
64. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA,. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 2000; 6 (8): 3046-3055.
65. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S,. Delivery of CD44 shRNA/nanoparticles within cancer cells: Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem 2009; 284 (18): 12432-12446.
66. Qian C, Wang Y, Chen Y, Zeng L, Zhang Q, Shuai X, Huang K,. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials 2013; 34 (26): 6175-6184.